ONeill Hugh Paul 4

What Happened
Hugh O'Neill, EVP and Chief Operations Officer of Keenova Therapeutics plc, received an award of 34,528 restricted stock units (RSUs) on February 25, 2026. The grant is reported as a derivative award at $0.00 per share (RSUs are settled in ordinary shares upon vesting). No cash was exchanged; the economic value to O'Neill will depend on Keenova's share price when the RSUs vest.

Key Details

• Transaction date: 2026-02-25; filing date: 2026-02-26 (timely filing).
• Award: 34,528 RSUs granted, reported at $0.00 (derivative securities).
• Vesting: RSUs will settle one-for-one into ordinary shares (F1) and vest ratably on each of the first three anniversaries of Feb 25, 2027 (F2). That implies partial vesting on Feb 25 of 2027, 2028 and 2029.
• Shares owned after transaction: not specified in the filing.
• Remarks: Filing also serves as notice to the issuer under Part V of the Companies Act 2014.

Context
This is a standard executive equity award intended for retention and alignment with shareholders; RSUs convert to ordinary shares only as they vest, so there is no immediate share sale or purchase. The grant itself is not a signal of near-term buying or selling — realized value will depend on future stock price at each vesting date.